Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options

Oct 01 2016

• By Lucie Ellis-Taitt

Listen to this article

Despite being able to show superiority over market leader AbbVie's Humira (adalimumab), Johnson & Johnson will need to invest heavily in order to drive uptake for guselkumab if the drug is successfully approved next year for the treatment of psoriasis.

Balloons — J&J's New Psoriasis Drug Will Have Stiff Competition If Approved On Back Of Strong PhIII Data • Source: Shutterstock

Johnson & Johnson's anti-interleukin-23 therapy, guselkumab, has produced stronger efficacy data in VOYAGE 1, the first ever Phase III study to directly compare an IL inhibitor against anti-TNF-alpha treatment Humira (AbbVie Inc.’s adalimumab) in psoriasis patients – but uptake might still be a challenge in the early treatment setting because of the number of cheaper alternatives on the market.

J&J is aiming to position guselkumab early in the psoriasis treatment algorithm by directly comparing it to the current standard...

More from Immunological

Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
Sanofi/Regeneron’s Dupixent: A First For COPD, But Not The Last
Mar 10 2025
• By Jessica Merrill
The IL-4/13 inhibitor was approved in the US for COPD, a blockbuster-sized indication, but the commercial ramp could take time and several competitors are on its heels.
Biogen Joins Molecular Glue Degrader Club with Neomorph Pact--Test-1
Dec 10 2024
• By Saba Afreen
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.